All In Biotech

NDA 020637 · Azurity

Gliadel

Carmustine · Intracranial · Alkylating Drug

Priority reviewOrphan

Last checked: Nov 20, 2026Latest source record: Dec 5, 2018 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1996

Sep 23, 1996

Approved uses

2

Original approval plus efficacy supplements

Registered trials

259

44 Phase 3, 18 recruiting

FAERS reports

4,717

4,619 serious, 1,214 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Dec 5, 2024.

GLIADEL Wafer is indicated for the treatment of patients with: newly-diagnosed high-grade glioma as an adjunct to surgery and radiation, and recurrent glioblastoma as an adjunct to surgery. GLIADEL Wafer is an alkylating drug indicated for the treatment of: newly-diagnosed high-grade glioma as an adjunct to surgery and radiation ( 1 ) and recurrent glioblastoma as an adjunct to surgery ( 1 )

Mechanism: The activity of GLIADEL Wafer is due to release of cytotoxic concentrations of carmustine, a DNA and RNA alkylating agent, into the tumor resection cavity. On exposure to the aqueous environment of the resection cavity, the anhydride bonds in the copolymer are hydrolyzed, releasing carmustine, carboxyphenoxypropane, and sebacic acid into the surrounding brain tissue.

Therapeutic areas: Oncology

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Feb 25, 2003 Supplement 16 · Efficacy · priority review ReviewLetterLabel
  • Sep 23, 1996 Original approval · Type 3 - New Dosage Form · priority review Review
1 products under this application
  • GLIADEL · CARMUSTINE 7.7MG · IMPLANT, INTRACRANIAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Carmustine" as an intervention, any sponsor and status, largest first.

All 259 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • off label use521
  • febrile neutropenia400
  • myelodysplastic syndrome301
  • disease progression292
  • mucosal inflammation256
  • thrombocytopenia252
  • pyrexia242
  • neutropenia211
  • pneumonia206
  • drug ineffective202
  • infection183
  • acute myeloid leukaemia172

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
200492
2005112
2006105
2007118
2008134
2009103
201090
2011147
2012144
2013139
2014101
2015194
2016126
2017247
2018337
2019351
2020375
2021311
2022292
2023440
2024298
2025229
2026232

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 445 on PubMed

Sponsor: Azurity

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.